PRECLINICAL ARTICLES
-
There's A Gap In Brain Tumor Research — Here's How We Fix It
Brain tumors are some of the most biologically complex and least improved indications. Biochemistry researcher and scientist Catherine Bladen, Ph.D., argues sustained focus is a key to driving real-world progress.
-
AI Drug Discovery Is Revealing The Preclinical Bottleneck
For the generative AI revolution in drug discovery to deliver on its promise, the industry needs more than better molecules, it needs a better pipeline architecture.
-
Beyond Biologics: A Biophysical Approach To Crohn's Disease
Research into a nano-amorphous approach suggests a new breakthrough in Crohn’s management may come from a shift toward modulating the biophysical environment of the gut.
-
Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics?
Thymic stromal lymphopoietin (TSLP) inhibition has firmly established itself as a strategy in respiratory disease. This article highlights some promising drug candidates and next-generation approaches.
-
What's Next For ADCs: How Combinations Will Help Define The Future Of Treatment
Insights gained from advancing ADC combination therapies in lung cancer are now shaping innovative approaches across multiple tumor types.
-
From "Live Drug" To Precision Tool: Redefining CAR T Safety
Through important chemistry and the right engineering, there’s new opportunity for CAR T therapeutics to target different forms of cancer with limited toxicity.
PRECLINICAL ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
-
Discover Curia’s cost-effective high-content immunofluorescence workflow using the Revvity Opera Phenix™ system to efficiently identify small molecule protein degraders with rich, multi-dimensional data.
-
New advances in chemomics, proteome mapping, and modern synthetic methods are redefining how quickly and precisely discovery teams can move from raw data to meaningful clinical momentum.
-
Explore how PCR works, what impacts reaction success, and how to troubleshoot common challenges with expert guidance and real lab examples designed to help you strengthen your PCR skills.
-
Gain insight into automating DNA size selection that shows how optimized bead ratios and programmable handling improve fragment recovery, consistency, and throughput.
-
Gain insight into an automated high‑input workflow that streamlines long‑read whole‑genome library prep, supporting large DNA fragments while reducing reagent use.
-
A streamlined workflow reduces reagent use and hands‑on time while preserving long‑read sequencing quality. See how multiplexed offer an efficient option for scaling or mobilizing sequencing efforts.
-
Understanding covalent warhead kinetics is key to reducing safety risks early in discovery. Learn about a new approach to GSH‑based measurements that offers clearer predictors of toxicity.
-
Gain insight into how late‑stage exchange and flow‑based methods enable efficient access to labeled molecules for pharmaceuticals, mechanistic studies, and analytical applications.
-
Examine a mirror‑image screening approach that eliminates DNA:RNA hybridization, revealing true binders and unlocking clearer, more productive DEL results for challenging RNA targets.
-
Improve accuracy and reduce stress with expert pipetting tips. Discover how technique and tool selection can boost precision and efficiency, ensuring consistent results across every lab workflow.
-
Scalable lentiviral vector production is moving beyond adherent systems. Learn how streamlined workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.
PRECLINICAL SOLUTIONS
-
Magnetic bead-based genomic DNA extraction kit.
-
Frees you from routine pipetting and provides excellent results
-
We have introduced the MAG and HEATMAG modules with you, the scientists, in mind.
-
MAGFLO magnetic beads are only available in Austria, Belgium, Denmark, France, Germany, Ireland, Netherlands, Sweden, Switzerland and the United Kingdom.
-
Explore how a data‑driven discovery model combines DEL screening, computational insights, and medicinal chemistry to accelerate hit‑to‑lead decisions, reduce risk, and enable efficient progression.
-
Chemomics transforms full DEL datasets into predictive insights. See how combining large-scale screening with clear computational models accelerates SAR understanding and strengthens confidence.
-
Generate human-relevant data with an Organ-Chip system that combines automation, imaging, and cost efficiency for faster, more confident insights for drug development and complex biological studies.
-
With 12 independent Emulations in one consumable, Chip-Array optimizes workflows and reduces cell requirements—delivering scalable, physiologically relevant models for advanced research.
-
From cancer models to high-throughput screening, Organ-Chip platforms accelerate development, improve safety, and support regulatory compliance for next-generation therapies.
-
With over 585,000-sq.-ft. of purpose-built space, our preclinical facilities across North America are designed to support your drug development journey, from early discovery to IND/NDA submission.
-
Altasciences specializes in lead optimization studies, helping you identify the most promising drug candidates through precise, data-driven preclinical screening. Our expert scientists tailor each study to your unique needs, utilizing efficient non-GLP screening protocols to accelerate decision-making. With streamlined study designs, clear data visualization, and rapid turnaround times, we provide actionable insights to advance your drug discovery pipeline.
-
See how our innovative capabilities and advanced technologies can optimize the development and manufacturing of complex synthetics for drug substances, medical devices, and diagnostic agents.
-
This human-relevant liver model featuring a rigid plastic is designed to minimize small-molecule drug absorption. Explore the specifications of this product engineered to model the liver.
-
As a leading partner in ocular therapy, Altasciences is at the forefront of ophthalmic drug development. Our integrated CRO/CDMO solutions can support your program from lead candidate selection to market. You will benefit from working with a single partner as your product advances through each phase of drug development—from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing. This could mean up to 40% in time savings.